Sago Palm (Cycad) Hepatotoxicosis in Dogs: Clinical Management

Bottom line

Sago palm (Cycas revoluta) ingestion is a life-threatening hepatotoxic emergency in dogs with no antidote — as of 2026, published case-fatality rates range from roughly 12% to 50%, and every plant part is toxic with seeds the most concentrated and most commonly ingested (1–2 seeds can be lethal) [1][2][3][4]. The toxic glucoside cycasin is hydrolyzed by gut bacteria to methylazoxymethanol (MAM), which alkylates DNA/RNA and drives centrilobular-to-midzonal hepatocellular necrosis plus GI injury [4][6]. Outcome hinges on early, aggressive decontamination — administration of activated charcoal is independently associated with survival (in one 130-dog series it reduced the odds of death by 82%) — layered onto intensive hepatic support [1][2]. Prognosis is guarded to poor once fulminant hepatic failure, coagulopathy, or encephalopathy develops.

Clinical facts

• Toxic dose: No established LD; ingestion of 1–2 seeds has been fatal. Seeds/nuts carry the highest cycasin concentration, but leaves, roots, and stem are all toxic [3][4].
• Toxic principles: Cycasin (→ methylazoxymethanol/MAM, the hepatotoxic/GI aglycone), the neurotoxic amino acid BMAA (β-methylamino-L-alanine), and an unidentified high-molecular-weight toxin [3][4][6].
• Onset: GI signs within ~15 minutes to several hours; hepatic injury peaks 24–72 h post-ingestion [3].
• Mortality: ~12.3% (Lake 2020, n=130) to 50% (Ferguson 2011, n=34); older/ASPCA figures span ~2–75% depending on case confirmation and severity [1][2][3][5].
• Antidote: None. Management = decontamination + hepatoprotection + supportive care [1][3][4].
• Key prognostic indicators: Higher presenting ALT, AST, and total bilirubin; lower initial and nadir albumin; thrombocytopenia (<200,000/µL) [1][2].

Toxic principles and mechanism

The principal hepatotoxin is cycasin, a methylazoxymethanol (MAM) glucoside present in all parts of Cycas revoluta and related cycads, with the highest concentration in the seeds/nuts [3][4]. As of 2026, the accepted mechanism is that cycasin is not intrinsically toxic until enteric bacterial β-D-glucosidase hydrolyzes it to the aglycone methylazoxymethanol (MAM) [4][6]. MAM is a potent alkylating agent: it methylates guanine moieties in DNA and RNA, interferes with template function, and inhibits nuclear and nucleolar RNA synthesis — producing centrilobular and midzonal coagulative hepatocellular necrosis and gastrointestinal mucosal injury [4][6].

Two additional toxins contribute to the syndrome. BMAA (β-methylamino-L-alanine) is a neurotoxic non-protein amino acid implicated in the CNS signs, and an unidentified high-molecular-weight compound is also described [3][4]. Because MAM generation depends on gut flora and the toxin is well absorbed, clinicians should treat any confirmed or strongly suspected ingestion as potentially lethal regardless of the amount reportedly consumed [3][4].

Clinical course by phase

Cycad toxicosis classically evolves through three overlapping phases; a given patient may present in any of them, and GI signs can be deceptively mild before hepatic failure declares itself [1][3].

Phase 1 — Gastrointestinal (≈15 min to several hours). Vomiting is the most consistent early sign, often with diarrhea (frequently hemorrhagic), hypersalivation, hyporexia/anorexia, abdominal pain, and lethargy [3][4]. In Lake's 130-dog series, 82.3% were symptomatic at presentation, most commonly with diarrhea and lethargy [2].

Phase 2 — Hepatotoxic (≈24–72 h). Acute hepatocellular necrosis produces marked ALT/AST elevations, rising ALP and total bilirubin, icterus, and hypoglycemia from hepatic failure. Synthetic failure yields coagulopathy (prolonged PT/aPTT, petechiae/ecchymoses, melena) and hypoalbuminemia, and hepatic encephalopathy may develop [1][3][4]. This is the phase that most often determines survival.

Phase 3 — Neurologic/terminal. Weakness, ataxia, tremors, and seizures reflect a combination of hepatic encephalopathy and direct neurotoxicity; progression to fulminant hepatic failure, DIC, and death occurs in severe cases [3][4]. Chronic survivors may develop ammonium biurate crystalluria, acquired portosystemic shunting, and hepatic parenchymal remodeling [4].

Diagnosis and clinicopathology

Diagnosis is clinical, anchored on a history of access to a sago palm/cycad plus compatible GI-then-hepatic signs; retained plant fragments in vomitus support it [3][4]. No confirmatory antemortem toxin assay is used in practice. As of 2026, work up every suspected case with a serial biochemistry panel, CBC (platelets), coagulation profile (PT/aPTT), blood glucose, and electrolytes [1][3].

Expect rising ALT and AST (hepatocellular), increasing ALP and total bilirubin (cholestasis/necrosis), hypoglycemia, and hypoalbuminemia [1][3]. Ferguson et al. found nonsurvivors had significantly higher presenting ALT (median 196 vs 113.5 U/L) and total bilirubin (0.5 vs 0.25 mg/dL) and lower initial albumin (2.9 vs 3.3 g/dL) and nadir albumin (1.9 vs 3.2 g/dL) than survivors; high AST was also a negative prognostic marker [1]. Lake et al. identified elevated initial ALT (with a better prognosis when ALT <125 U/L) and thrombocytopenia (<200,000/µL) as negative prognostic indicators [2]. Bile acids/ammonia and abdominal ultrasound help characterize hepatic function and parenchyma; defer liver biopsy until coagulation is corrected [3].

Decontamination

Decontamination is the single most impactful intervention and should not be delayed. As of 2026, activated charcoal administration is independently associated with survival — in Lake's 130-dog series it reduced the odds of death by 82%, with additional benefit in dogs with elevated initial ALT, and Ferguson found charcoal at presentation associated with longer survival [1][2].

• Emesis: Induce in recently exposed, asymptomatic patients that are not already vomiting — apomorphine, or 3% hydrogen peroxide — provided airway/mentation are protected [3].
• Activated charcoal: 1–5 g/kg PO once, or for multi-dose therapy 1–2 g/kg PO every 4–6 h for 24 h, given the enterohepatic recirculation of the toxin; include a cathartic (e.g., sorbitol) with the first dose only [3][4]. Multi-dose (repeated) charcoal is supported for this toxicant [3].
• Gastric lavage: Consider in large, recent ingestions or when emesis is contraindicated/unproductive, followed by charcoal instillation [3].

Time NAC dosing relative to oral charcoal (give NAC IV, or separate oral doses) to avoid charcoal binding the antioxidant [3].

Hepatic support and antidotal therapy

There is no antidote; care is intensive hepatoprotective and supportive. Doses below are representative from a DACVECC/DABT clinical reference and standard toxicology practice; several hepatoprotectants are used off-label in dogs [3].

• IV crystalloids: Balanced isotonic fluids for perfusion and diuresis; some clinicians avoid lactate-containing fluids in significant hepatic injury [3].
• Dextrose: Supplement (e.g., 2.5–5% in fluids, titrated) for the hypoglycemia of hepatic failure [3].
• N-acetylcysteine (NAC): 140–280 mg/kg IV (preferred) or PO once, then 70 mg/kg IV/PO every 6 h for 2–3 days — replenishes glutathione and limits oxidative hepatic injury [3].
• S-adenosylmethionine (SAMe): 18–20 mg/kg PO once daily (given on an empty stomach) [3].
• Silymarin/silybin (milk thistle): Antioxidant hepatoprotectant; commonly given as a silybin-phosphatidylcholine complex per label/product dosing [3][4].
• Vitamin K1: 1 mg/kg PO or SC q12h if coagulopathic (SC, not IV, to avoid anaphylactoid reactions) [3].
• Fresh frozen plasma: 10–20 mL/kg IV for active bleeding or documented coagulopathy, to replace clotting factors [3].
• Antiemetics / GI protectants: Maropitant, ondansetron, or dolasetron for vomiting; proton-pump inhibitors, H2 antagonists, and sucralfate for GI ulceration [3].
• Hepatic encephalopathy: Lactulose (to trap ammonia and produce catharsis) plus consideration of gut-directed antibiotics; control seizures with levetiracetam (20–60 mg/kg IV) or a benzodiazepine as needed [3][4].

Monitoring and prognosis

Monitor intensively for at least 72 hours, since hepatic injury peaks 24–72 h after ingestion and early GI signs underestimate severity [1][3]. As of 2026, recommended in-hospital monitoring is daily (or more frequent) serial liver enzymes and total bilirubin, blood glucose, PT/aPTT and platelet count, albumin, electrolytes, and PCV/TS, plus bile acids or ammonia to track hepatic function [1][3]. Trend the values — a rising ALT/AST/bilirubin, falling albumin, worsening coagulation, or new thrombocytopenia signal deterioration and a worse prognosis [1][2].

Prognosis is guarded to poor once fulminant hepatic failure, coagulopathy, or encephalopathy is established, and better with early aggressive decontamination and normal-to-mildly-elevated liver values [1][2][3]. Survival estimates vary widely by population and case confirmation: ~12.3% mortality in Lake's referral series (with charcoal treatment), 50% in Ferguson's confirmed-toxicosis cohort, and Merck cites 34–64% survival depending on confirmation level [1][2][4]. Counsel owners candidly: cycad ingestion is a true emergency, and the interval from ingestion to decontamination is the most modifiable determinant of outcome [1][2].

Frequently Asked Questions

What is the survival rate for sago palm (cycad) toxicosis in dogs?

As of 2026, published case-fatality varies by population and case confirmation. In Ferguson et al.'s cohort of 34 dogs with confirmed cycad toxicosis, 17/34 (50%) died or were euthanized [1]. In a larger referral series of 130 dogs (Lake et al.), overall mortality was 12.3% — lower, in part because most received activated charcoal [2]. The Merck Veterinary Manual cites 34–64% survival depending on how cases were confirmed [4]. Bottom line: outcome is highly dependent on severity of hepatic injury and how quickly decontamination occurs.

How many sago palm seeds are dangerous to a dog?

Ingestion of as few as 1–2 seeds can be lethal [3][4]. Seeds (nuts) contain the highest concentration of cycasin and are the part most commonly and most seriously ingested, but leaves, roots, and stem are all toxic — so any confirmed ingestion should be treated as potentially fatal regardless of the reported amount [3][4].

Is multi-dose activated charcoal indicated for sago palm ingestion?

Yes — activated charcoal is the single most important intervention and is independently associated with survival (an 82% reduction in the odds of death in one 130-dog series) [1][2]. Because the toxin undergoes enterohepatic recirculation, repeated (multi-dose) charcoal is supported: 1–5 g/kg PO once, or 1–2 g/kg PO every 4–6 h for 24 h, with a cathartic (e.g., sorbitol) included in the first dose only [3][4]. Separate oral N-acetylcysteine from oral charcoal, or give NAC IV, to avoid binding [3].

Which hepatoprotectants are used for cycad hepatotoxicosis?

Standard hepatoprotective therapy layers several antioxidants: N-acetylcysteine 140–280 mg/kg IV/PO once then 70 mg/kg q6h for 2–3 days; S-adenosylmethionine (SAMe) 18–20 mg/kg PO once daily; and silymarin/silybin (milk thistle) per product dosing [3][4]. Coagulopathy is managed with vitamin K1 1 mg/kg SC/PO q12h and fresh frozen plasma 10–20 mL/kg IV as needed [3]. Several of these are used off-label in dogs. There is no antidote — these agents support the liver while it regenerates [3][4].

How long should you monitor liver values after a cycad ingestion?

Monitor for at least 72 hours, because hepatocellular injury peaks 24–72 h after ingestion and early GI signs can precede — and understate — the hepatic phase [1][3]. Serial ALT/AST, total bilirubin, blood glucose, PT/aPTT, platelet count, albumin, and electrolytes should be trended (typically daily or more often while hospitalized); a dog with persistently normal liver values and no coagulopathy at 72 h has a substantially better prognosis [1][3].

What are the negative prognostic indicators in sago palm toxicosis?

Higher presenting ALT, AST, and total bilirubin, and lower initial and nadir albumin, distinguished nonsurvivors from survivors in Ferguson et al. [1]. Lake et al. added elevated initial ALT (better prognosis when ALT <125 U/L) and thrombocytopenia (<200,000/µL) as negative indicators [2]. Clinically, worsening trends — rising enzymes/bilirubin, falling albumin, developing coagulopathy or encephalopathy — carry a guarded-to-poor prognosis [1][2][3].

Is there an antidote for sago palm poisoning in dogs?

No — there is no specific antidote for cycasin/MAM toxicity [1][3][4]. Management rests entirely on early decontamination (emesis if appropriate, activated charcoal ± gastric lavage) and intensive supportive/hepatoprotective care: IV fluids, dextrose for hypoglycemia, antiemetics and GI protectants, hepatoprotectants (NAC, SAMe, silymarin), and vitamin K1/plasma for coagulopathy [3][4]. The speed of decontamination is the most modifiable factor in outcome [1][2].

Should induced emesis be attempted at home before coming to the clinic?

Emesis is best performed under veterinary supervision. It is only appropriate in a recently exposed, asymptomatic dog that is not already vomiting and can protect its airway; a patient already vomiting, obtunded, or seizing should not be made to vomit [3]. Given how rapidly cycad ingestion becomes life-threatening, the priority is immediate transport to a veterinary facility (or contact with ASPCA APCC/Pet Poison Helpline) for professionally directed decontamination [3][5].